<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800058</url>
  </required_header>
  <id_info>
    <org_study_id>CaPr-RTCTC-01/PI 197</org_study_id>
    <nct_id>NCT01800058</nct_id>
  </id_info>
  <brief_title>Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy</brief_title>
  <official_title>Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The detection and quantification of Circulating tumor cells CTCs in peripheral blood of
      patients with prostate adenocarcinoma may be useful at least for:

      Getting a correct stratification of patients with high-risk prostate cancer (PCa).

      Set the prognosis at baseline. Evaluate the response to different treatments (predictive
      value and monitoring).

      Establish individualized therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective analysis of biologic samples from peripheral blood of 65 patients with localized
      high-risk PCa (NCCN 2011) treated with RTC-3D-IMRT combined with AD.

      Following the sign of the informed consent of the patient, the blood samples will be analyzed
      for CTCs using an immunomagnetic method based on the CellSearch system (Veridex), in 4
      periods of time:

        1. prior to any treatment;

        2. following AD and prior to RT; and

        3. following the end of RT (1-3 months afterwards).

        4. six to twelve months following the end of RT in those patients with 0 CTCs in the first
           determination and positive CTCs in the second or third determination

      Comparison between the expression of CTCs in peripheral blood before and following AD and RT
      will be performed. The quantification of the CTCs obtained in these phases of treatment will
      be correlated with the treatment results in terms of biochemical failure according to Phoenix
      definition, distant metastasis rate and overall survival to identify a significant prognostic
      relationship and to determine the potential effect of the treatment in the number of CTCs Our
      working group will include 65 patients because the amount is based on routine clinical
      activity can be safely enrolled in the project development time by the participating centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</measure>
    <time_frame>Basal</time_frame>
    <description>Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</measure>
    <time_frame>Post-neoadjuvant hormone therapy and prior to radiotherapy</time_frame>
    <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</measure>
    <time_frame>Post-radiotherapy</time_frame>
    <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</measure>
    <time_frame>9 - 12 months post-radiotherapy in cases with positivation after basal visit</time_frame>
    <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical Failure-free Survival;</measure>
    <time_frame>4 years</time_frame>
    <description>Phoenix criteria (PSA Nadir +2 ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free Survival</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as freedom from distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause Specific Survival</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as death caused by prostate cancer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">68</enrollment>
  <condition>Patients With High-risk Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Circulating prostatic tumor cells in the peripheral blood</arm_group_label>
    <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Prospective analysis of biological material from samples of peripheral blood (PB) of patients
      with high risk prostate cancer treated with dose escalation RT combined with androgen
      deprivation (AD)

      The sampling of PB for detection of CTCs was performed at 4 timepoints:

        -  Before starting any treatment

        -  Prior to the start of RT and after neoadjuvant AD

        -  At the end of RT (1-3 months)

        -  6-12 months following the end of RT in patients with 0 CTCs in the 1º determination and
           positive CTCs in the 2º or 3º determination.

      A cut off of 0 vs ≥ 1 CTC/7.5 mL blood was defined as a threshold for negative versus
      positive CTCs status.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with prostate cancer at high risk (NCCN 2011), AJCC stage IIB-III,
        treated with 3D-CRT, IMRT dose escalation (with androgen deprivation (DA))
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged &gt; 18 with capacity to give informed consent.

          -  Patients with histologically confirmed prostate cancer.

          -  Patients with a high risk factor: PSA&gt; 20 ng / ml, Gleason 8-10 and / or stage T3a-b,
             N0M0 (NCCN 2011, stage IIB-III AJCC classification 2010). Staging by:
             Histology-Gleason score-, PSA, TR, ECO TR, CT, MRI.

          -  Patients who accept radical treatment with radiotherapy.

          -  Patients who give written informed consent to participate in the study

        Exclusion Criteria:

          -  Any patient diagnosed with prostate cancer, which does not meet the prerequisites.

          -  Any patients with another malignancy diagnosed in the past 5 years (except basal cell
             or squamous cell carcinoma of skin).

          -  Any patient who has prostate biopsy performed 7 days prior to study entry.

          -  Patients who have received prior treatment with hormonal therapy, chemotherapy or
             radiotherapy.

          -  Patients with PSA&gt; 100 ng / ml.

          -  Any situation or condition of the patient which in the opinion of the investigator,
             advised against participation in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Almudena Zapatero, MD, PhD, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Department_Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Damber JE, Aus G. Prostate cancer. Lancet. 2008 May 17;371(9625):1710-21. doi: 10.1016/S0140-6736(08)60729-1. Review.</citation>
    <PMID>18486743</PMID>
  </reference>
  <reference>
    <citation>Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1028-33. doi: 10.1016/j.ijrobp.2007.11.066. Epub 2008 Feb 14.</citation>
    <PMID>18280056</PMID>
  </reference>
  <reference>
    <citation>Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74. Epub 2007 Aug 31.</citation>
    <PMID>17765406</PMID>
  </reference>
  <reference>
    <citation>Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 1;26(4):585-91. doi: 10.1200/JCO.2007.13.9881. Epub 2008 Jan 2.</citation>
    <PMID>18172188</PMID>
  </reference>
  <reference>
    <citation>Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.</citation>
    <PMID>18413638</PMID>
  </reference>
  <reference>
    <citation>Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007 Apr 1;13(7):2023-9.</citation>
    <PMID>17404082</PMID>
  </reference>
  <reference>
    <citation>Zapatero A, Ríos P, Marín A, Mínguez R, García-Vicente F. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation? Clin Oncol (R Coll Radiol). 2006 Oct;18(8):600-7.</citation>
    <PMID>17051950</PMID>
  </reference>
  <reference>
    <citation>Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005 Apr;65(4):713-8.</citation>
    <PMID>15833514</PMID>
  </reference>
  <reference>
    <citation>Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002 Jul;8(7):2073-84.</citation>
    <PMID>12114406</PMID>
  </reference>
  <reference>
    <citation>Zapatero A, Mínguez R, Nieto S, Martín de Vidales C, García-Vicente F. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? Eur Urol. 2009 Apr;55(4):902-9. doi: 10.1016/j.eururo.2008.04.076. Epub 2008 May 7.</citation>
    <PMID>18485578</PMID>
  </reference>
  <reference>
    <citation>Zapatero A, García-Vicente F, Martín de Vidales C, Cruz Conde A, Ibáñez Y, Fernández I, Rabadán M. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1279-85. doi: 10.1016/j.ijrobp.2010.07.1975. Epub 2010 Oct 6.</citation>
    <PMID>20932659</PMID>
  </reference>
  <reference>
    <citation>Olivier Gómez C, Carballido Rodríguez J. [Circulating tumor cells: isolation, quantification, and relevance of their translation into clinical practice]. Actas Urol Esp. 2010 Jan;34(1):3-5. Spanish.</citation>
    <PMID>20223125</PMID>
  </reference>
  <reference>
    <citation>Alix-Panabières C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008 Aug 15;14(16):5013-21. doi: 10.1158/1078-0432.CCR-07-5125. Review.</citation>
    <PMID>18698019</PMID>
  </reference>
  <reference>
    <citation>Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med. 2006 Mar;12(3):130-9. Epub 2006 Feb 20. Review.</citation>
    <PMID>16488189</PMID>
  </reference>
  <reference>
    <citation>Cabanes A, Vidal E, Aragonés N, Pérez-Gómez B, Pollán M, Lope V, López-Abente G. Cancer mortality trends in Spain: 1980-2007. Ann Oncol. 2010 May;21 Suppl 3:iii14-20. doi: 10.1093/annonc/mdq089.</citation>
    <PMID>20427355</PMID>
  </reference>
  <reference>
    <citation>Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer. 2000 Aug;36(13 Spec No):1681-94. Review.</citation>
    <PMID>10959054</PMID>
  </reference>
  <reference>
    <citation>Llanes L, Ferruelo A, Luján M, Pascual C, García-Mediero JM, Berenguer A. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(3):248-52.</citation>
    <PMID>15897916</PMID>
  </reference>
  <reference>
    <citation>Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005 Sep 20;23(27):6561-8.</citation>
    <PMID>16170164</PMID>
  </reference>
  <reference>
    <citation>Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74.</citation>
    <PMID>16798415</PMID>
  </reference>
  <reference>
    <citation>Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006 Jun;33(3 Suppl 9):S9-14. Review.</citation>
    <PMID>16797376</PMID>
  </reference>
  <reference>
    <citation>Bolla M, Collette L, Van Tienhoven G, et al. Ten-year results of long-term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study. Int J Radiat Oncol Biol Phys 2008;72:S30-S31.</citation>
  </reference>
  <reference>
    <citation>L. Resel Folkersma, C. Olivier Gómez, L. San José Manso, et al. Cuantificación Inmunomagnética De Células Tumorales Circulantes En Pacientes Con Cáncer De Próstata: Correlación Clínica Y Patológica. Arch. Esp. Urol. 2010; 63 (1): 23-31</citation>
  </reference>
  <results_reference>
    <citation>Zapatero A, Gómez-Caamaño A, Cabeza Rodriguez MÁ, Muinelo-Romay L, Martin de Vidales C, Abalo A, Calvo Crespo P, Leon Mateos L, Olivier C, Vega Piris LV. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study. Radiat Oncol. 2020 Jun 1;15(1):137. doi: 10.1186/s13014-020-01577-5.</citation>
    <PMID>32487218</PMID>
  </results_reference>
  <results_reference>
    <citation>A. Zapatero, A. Gomez Caamaño, M. D. L. A. Cabeza Rodriguez, L. Muinelo-Romay, C. Martin de Vidales C, A. Abalo, et al. Monitoring of Circulating Tumor Cells in Patients With High-Risk Nonmetastatic Prostate Cancer Treated With Radiation Therapy and Hormones: Preliminary Data of an Observational Prospective Phase 2 Study. International Journal of Radiation Oncology • Biology • Physics, Vol. 99, Issue 2, E280</citation>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <results_first_submitted>May 21, 2019</results_first_submitted>
  <results_first_submitted_qc>June 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2020</results_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT01800058/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>66 patients included: 2 patients were not included in the final enrollment due to inegibility criteria</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
          <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CTCs Analysis</title>
          <description>Prospective analysis of biologic samples from PB of 65 patients with localized high-risk PCa (NCCN 2011) treated with RTC-3D-IMRT combined with ADT. Following the sign of the informed consent of the patient, the blood samples will be analyzed for CTCs using an immunomagnetic method based on the CellSearch system in 4 periods of time:
Prior to any treatment (baseline- Time 1)
Following ADT and prior to RT (Time 2)
Following the end of RT (1-3 months afterwards) (Time 3)
Following 9 -12 after RT in those cases in cases of one turn (+) in CTCs in the 2nd or 3rd determination</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="53" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median PSA (ng/mL)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" lower_limit="3.2" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA pre-treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 10 ng/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10 - 20 ng/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 20 ng/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason score</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gleason sum =&lt; 6 Better prognosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason sum = 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason sum = 8 - 10 Worst prognosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical T Stage according to AJCC seventh edition</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>T1 Best prognosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3 Worst prognosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical N Stage according to AJCC seventh edition</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>N0 Best prognosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1 Worst prognosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Radiotherapy dose (Gy)</title>
          <units>Gy</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>3D Conformal RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.3" lower_limit="74.8" upper_limit="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMRT-IGRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.7" lower_limit="70.6" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</title>
        <description>Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline.</description>
        <time_frame>Basal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
            <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</title>
          <description>Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with 0 CTCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants with =&gt;1 CTCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</title>
        <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
        <time_frame>Post-neoadjuvant hormone therapy and prior to radiotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
            <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</title>
          <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with 0 CTCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants with =&gt;1 CTCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</title>
        <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
        <time_frame>Post-radiotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
            <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</title>
          <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with 0 CTCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants with =&gt;1 CTCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</title>
        <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
        <time_frame>9 - 12 months post-radiotherapy in cases with positivation after basal visit</time_frame>
        <population>Patients with positivation after basal visit</population>
        <group_list>
          <group group_id="O1">
            <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
            <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Circulating Tumor Cells in the Peripheral Blood</title>
          <description>(Initially a cutoff point of &gt; 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline).</description>
          <population>Patients with positivation after basal visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with 0 CTCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants with =&gt;1 CTCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Failure-free Survival;</title>
        <description>Phoenix criteria (PSA Nadir +2 ng/mL)</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
            <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Failure-free Survival;</title>
          <description>Phoenix criteria (PSA Nadir +2 ng/mL)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Defined as death due to any cause</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
            <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Defined as death due to any cause</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metastasis-free Survival</title>
        <description>Defined as freedom from distant metastasis</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
            <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
          </group>
        </group_list>
        <measure>
          <title>Metastasis-free Survival</title>
          <description>Defined as freedom from distant metastasis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause Specific Survival</title>
        <description>Defined as death caused by prostate cancer</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
            <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
          </group>
        </group_list>
        <measure>
          <title>Cause Specific Survival</title>
          <description>Defined as death caused by prostate cancer</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Circulating Prostatic Tumor Cells in the Peripheral Blood</title>
          <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative of colon volvulus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastric adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastric GIST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ureter cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral estenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumomia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bronchoaspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Late rectal symptoms Grade &gt;= 2</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Late urinary symptoms Grade &gt;= 2</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Almudena Zapatero, MD PhD</name_or_title>
      <organization>Hospital Universitario de La Princesa</organization>
      <phone>+34 91 520 23 15</phone>
      <email>almudena.zapatero@salud.madrid.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

